Mr. Sushanta Sarkar’s academic training began at Bangladesh’s University of Dhaka, which is where he earned his Bachelor’s degree in pharmacy in 2011 and his Master’s degree in pharmaceutical technology the following year focusing on the development and improvement of drug dosage forms that can be taken by mouth. Afterward, at Lamar University in Beaumont, Texas, he also completed a Master’s degree in chemistry and biochemistry in 2014, where his research was devoted to basic cancer biology with a further concentration in understanding the underlying causes of cancer. Subsequently, Mr. Sarkar worked for two years as a graduate research assistant in the Department of Pharmaceutical Science at the Texas Tech University Health Sciences Center. His research was focused on the discovery, development, and application of small molecules in the treatment of cancers, especially breast, lung, and prostate cancers. One of the small molecules he had developed is undergoing clinical trials. Recently, Mr. Sarkar has completed his Doctor of Pharmacy (PharmD) degree from the Appalachian College of Pharmacy, Oakwood, VA. During his PharmD studies he made significant contributions to the development of treatment options for various types of cancer as well as a multidisciplinary approach to diabetic management that is focused on underserved rural areas throughout the United States. Additionally, he was involved in testing the chemical stability of naloxone, an opioid overdose reversal medication. He had laid the groundwork for saving money by extending the usability of antidotes for reversing opioid overdoses. This assists in solving major health care problems by increasing the access of appropriate drugs in society and reducing costs for the U.S. government.

Thus far, Mr. Sushanta Sarkar has published 7 peer-reviewed articles in leading journals in his field. His work has been cited 112 times by researchers from all over the world. Therefore, I am confident that it will continue to have a considerable impact on the field of cancer research in the United States and beyond. Mr. Sarkar has contributed to the field by carrying out review duties for well-regarded journals such as Technology in Cancer Research & Treatment. Additionally, he serves as an associate editor for MOJ Bioequivalence and Bioavailability.